AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

Future Priorities for NIAID’s HIV Prevention Research

Future Directions for NIAID HIV Research

As we begin to discuss the restructuring of NIAID’s clinical trials networks, let us first focus on the Institute’s HIV prevention research agenda. Developing new biomedical tools that can safely and effectively prevent HIV acquisition and transmission is critical to addressing the global HIV/AIDS pandemic. Currently, we are exploring several promising HIV prevention strategies that,…

Restructuring NIAID’s HIV/AIDS Clinical Trials Networks

Future Directions for NIAID HIV Research

Over the next several weeks, the National Institute of Allergy and Infectious Diseases (NIAID) will post a series of entries here on AIDS.gov related to planning for the future of NIAID’s HIV/AIDS clinical trial networks. The awards supporting the six current HIV/AIDS networks are set to expire in 2013 and 2014. Building on the success…

Pursuing a “Cure” for HIV/AIDS – Two Distinct Approaches

Dr. Carl Dieffenbach, PhD

Contrary to what you may have heard or read on the Internet, there is currently no cure for HIV/AIDS. While some say that there may never be a cure, I believe there is reason for hope. That’s because some of our best scientists are working on two distinct approaches to finding a cure for HIV/AIDS,…

Keeping it Real: Understanding the Changing Landscape of HIV/AIDS Clinical Trials Communication

blog.aids.gov

Earlier this month we presented at a symposium of the HIV/AIDS Network Coordination Project’s (HANC) Communications Working Group. We asked Amy Ragsdale, HANC Special Projects Coordinator to tell us a little more about the Working Group and how they are using new media. The HIV/AIDS Network Coordination (HANC) works with the six HIV/AIDS clinical trials…

May 18: HIV Vaccine Awareness Day

blog.aids.gov

May 18, 2010 will mark HIV Vaccine Awareness Day (HVAD), an annual observance day that recognizes the thousands of volunteers, community leaders, health professionals, and scientists that work to develop a safe and effective preventive HIV vaccine. The National Institute of Allergy and Infectious Diseases (NIAID) – the Federal sponsor for HVAD – hopes the…

Drug Regimen with Short Pauses Controls HIV and Could Lower Costs, Toxicity

blog.aids.gov

Antiretroviral drugs for HIV infection usually are taken daily, and interrupting treatment for long periods of time has proven detrimental. However, a clinical trial in Uganda has found that pausing antiretroviral therapy (ART) for just two days every week is at least as effective as taking ART continuously over a 72-week period. In addition, the…

Putting TLC+ to the Test

Listen:

Javascript and flash are required to play this audio file.

Download MP3
Dr. Carl Dieffenbach, PhD

If we routinely test everyone for HIV and treat those who are infected, could we bring an end to the HIV/AIDS epidemic? The test and treat concept, modeled on data from South Africa by scientists at the World Health Organization, is a provocative HIV prevention strategy. According to mathematical modeling, a successfully implemented test and…

Goals of a Social Networking Symposium for NIH Staff

STEP: Staff Training in Extramural Programs

AIDS.gov note: Earlier this month, AIDS.gov presented an overview on using new and social media to approximately 400 Federal staff from the National Institutes of Health. (The session was offered both live and via webcast.) We applaud NIH’s commitment to providing ongoing educational opportunities for their staff. Megan Morena, Janice Nall, Miguel Gomez To learn…